Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01114230 (Clinical Trial / AGS-16M8F)

Study Title
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer (NCT01114230)

Trial Description
The purpose of this dose escalation study is to examine the safety and pharmacokinetics (PK) of AGS-16M8F (also known as AGS 16C3F) administered in subjects with advanced renal cell carcinoma.

The trial is sponsored by Agensys/Astellas Pharma Inc.

Study Data

  • Condition: Advanced Kidney Cancer
  • Interventions:
    • Drugs used in this trial
      • AGS-16M8F
  • Phase: I
  • Enrollment: 26
  • Start: August 2010
  • Completion: November 2012
  • Last Verified: December 2012

Study Schematic 

CT01114230

Return to drup map


Last Editorial review: August 28, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar